Goldman Sachs reiterated coverage on Reata Pharmaceuticals with a new price target

3/1/22 10:47:55 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Goldman Sachs reiterated coverage of Reata Pharmaceuticals with a rating of Neutral and set a new price target of $34.00 from $39.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RETA

Date	Price Target	Rating	Analyst
7/6/2023	$140.00	Outperform	TD Cowen
6/12/2023	$80.00 → $115.00	Market Perform → Outperform	SVB Securities
10/19/2022	$75.00	Buy	Guggenheim
3/24/2022	$91.00	Buy	Goldman
3/1/2022	$39.00 → $34.00	Neutral	Goldman Sachs
12/9/2021	$39.00	Buy → Neutral	Goldman Sachs
12/9/2021	$110.00 → $37.00	Outperform → Neutral	Robert W. Baird
12/9/2021	$112.00 → $68.00	Overweight	Cantor Fitzgerald